Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation

Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI). Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunol Res
Main Authors: Kim, Kyung Eun, Park, Sunyoung, Cheon, Soyoung, Kim, Dong Yeon, Cho, Dae Jin, Park, Jeong Min, Hur, Dae Young, Park, Hyun Jeong, Cho, Daeho
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6330826/
https://ncbi.nlm.nih.gov/pubmed/30687767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/9580561
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados